Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SLICK Trial: Cirtuvivint + Irinotecan in Relapsed Small Cell Lung Cancer
NCT07155200Phase 2Recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Dec 2025
- Primary completion
- Jul 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cirtuvivint in small cell lung cancer (SCLC), sponsored by Washington University School of Medicine. Started Dec 2025; status: recruiting.
02
Drugs
cirtuvivint
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07155200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07155200.